A survey published this week found that 93 percent of researchers who study cancer disparities — the differences in cancer rates, treatment access, and outcomes across racial, economic, and geographic lines — reported that federal policy changes have affected their work. Federal funding for this category of research has declined since last year. In some cases, grants have been terminated. In others, new applications have gone unfunded in cycles where they would previously have been supported.
Cancer disparity research is not a peripheral field. The variation in cancer outcomes across American populations is one of the most significant and persistent public health inequities in the country. Black Americans are more likely to die from prostate cancer, colorectal cancer, and several other malignancies than white Americans with the same diagnosis. Rural Americans face later-stage diagnoses partly because screening access is limited. Low-income patients are more likely to delay treatment for financial reasons and more likely to lack the support systems that improve adherence to treatment protocols. Understanding why these gaps exist and how to close them requires exactly the kind of targeted research that is now being defunded.
The framing that has accompanied some of the funding reductions treats disparity research as ideologically motivated — as a category of inquiry shaped by political commitments rather than scientific questions. That framing is worth examining carefully. The existence of differential cancer outcomes across populations is not a political position. It is a measurable fact, documented in decades of epidemiological literature, that has biological, behavioral, environmental, and structural components that are all legitimate subjects of scientific inquiry. Choosing not to fund that inquiry does not make the disparities disappear. It makes them less understood.
The 93 percent figure in the survey is striking because it is not a marginal response. When the overwhelming majority of researchers in a field report that their work has been affected by policy changes, it suggests a systematic rather than incidental disruption. The researchers who are not receiving funding are not conducting other research instead. They are leaving the field, redirecting to fundable questions, or training fewer students. The institutional capacity to do this work is being eroded in ways that will take years to rebuild.
The patients whose outcomes this research was designed to improve did not become less sick when the funding changed. The disparities that drive their worse outcomes did not narrow because the researchers studying them lost their grants. If you want to know what the federal health research agenda is prioritizing right now, and what it is no longer prioritizing, this is one of the clearest signals available.
Independent reporting. Real stories. No agenda but truth.
